Research and Markets (http://www.researchandmarkets.com/research/r5dd5r/china_insulin) has announced the addition of the "China Insulin Market Review to 2018 - Increasing Focus on R&D Investments" report to their offering.

The industry research publication titled China Insulin Market Review to 2018- Increasing Focus on R&D Investments' presents a comprehensive analysis of market size by volume and value of major types of insulin consumed in China. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in China. The future analysis of the market has also been discussed in the report.

The prevalence of diabetes in China has grown from 1% per capita in 1980 to more than 12% in 2013, making it the country with the most diabetic cases globally. In addition to 148 million people with pre-diabetes, 98.4 million people were diagnosed with diabetes in the country in 2013. In the near future, 6%-7% of those with pre-diabetes will be added to the existing diabetic population. Additionally, 40% of the youth aged 18-29 are potential diabetes patients with a high risk of stroke, heart disease and renal failure. Thus, the disease has become a matter of grave concern for the country and its wellbeing in the future.

Diabetes has reached catastrophic levels in China. According to the International Diabetes Federation, 98.4 million people in China were diagnosed as diabetic in 2013, representing the country with the largest diabetes cases in the world.

The rising epidemic of diabetes in China and its economic wellbeing has attracted the major insulin enterprises operating globally. Companies such as Novo Nordisk, Eli Lilly and Sanofi Aventis capture a large proportion of the market, whereas domestic players including Tonghua Dongbao and Shanghai Fosun Pharmaceutical share a small fraction of the Chinese insulin market.

Since analog insulin is emerging as the favored choice amongst the diabetic patients in the country, the vast and superior portfolio offered by the foreign multinationals has assisted them in constricting the market. These companies are also carrying out extensive R&D within the country in order to understand the local trends and supplying corresponding solutions.

Key Topics Covered:

1. Asia Pacific Insulin Market Introduction

2. China Insulin Market Introduction

3. China Insulin Market Size by Sales Value and Volume, 2008-2013

4. China Insulin Market Segmentation, 2008-2013

5. Government Regulations and Support Schemes for China Insulin Market

6. Trends and Developments in China Insulin Market

7. Growth Drivers in China Insulin Market

8. Market Shares of Major Companies in China Insulin Market

9. Company Profiles of major Players in China Insulin Market

10. China Insulin Market Future Outlook and Projections, 2014-2018

11. Macroeconomic Factors in China Insulin Market, 2008-2018

12. Appendix

Companies Mentioned

  • BJ Ganli Pharmaceutical
  • Eli Lilly
  • Novo Nordisk
  • Sanofi Aventis
  • Tonghua Dongbao

For more information visit http://www.researchandmarkets.com/research/r5dd5r/china_insulin